Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2019)

Historic Income from Continuing Operations for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' Income from Continuing Operations fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 3688.5%. This contributed to the annual value of -$4.3 million for FY2019, which is 3104.1% down from last year.
  • Per Monopar Therapeutics' latest filing, its Income from Continuing Operations stood at -$1.2 million for Q4 2019, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
  • Over the past 5 years, Monopar Therapeutics' Income from Continuing Operations peaked at -$373839.0 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
  • In the last 3 years, Monopar Therapeutics' Income from Continuing Operations had a median value of -$828354.0 in 2018 and averaged -$2.0 million.
  • Data for Monopar Therapeutics' Income from Continuing Operations shows a peak YoY increase of 9551.92% (in 2018) and a maximum YoY decrease of 14001.24% (in 2018) over the last 5 years.
  • Monopar Therapeutics' Income from Continuing Operations (Quarter) stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
  • Its Income from Continuing Operations was -$1.2 million in Q4 2019, compared to -$759448.0 in Q3 2019 and -$932109.0 in Q2 2019.